President and Chief Executive Officer · TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Kåre Schultz

A named executive officer of TEVA PHARMACEUTICAL INDUSTRIES in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$15,724,518

Salary $2,000,000Stock awards $9,999,970

FY2019: $11,596,564

1st of 5 named executive officers at Teva Pharmaceutical Industries by FY2020 total.

5 named officers on file for TEVA PHARMACEUTICAL INDUSTRIES, FY2020

Kåre Schultz’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 8 equity grants, each cited to its filing
  • TEVA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how TEVA PHARMACEUTICAL INDUSTRIES’s whole pay program stands against its peers

  • TEVA PHARMACEUTICAL INDUSTRIES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TEVA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2021 (DEF 14A).

Free

Get Kåre Schultz’s full pay file as a PDF — free

More than this page: up to 10 years of Kåre’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kåre Schultz compensation by year

TEVA PHARMACEUTICAL INDUSTRIES Summary Compensation Table · all 4 fiscal years held
In US dollars, as TEVA PHARMACEUTICAL INDUSTRIES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$333,333$2,000,000$2,000,000$2,000,000
Bonus$0$20,000,000$0$0
Stock awards$14,229,808$4,499,977$5,999,977$9,999,970
Option awards$2,000,009$1,500,019$0$0
Non-equity incentive$0$3,790,360$2,869,720$3,055,920
Pension and deferred compensation$0$0$0$0
All other$464,591$679,519$726,867$668,628
Total$17,027,741$32,469,875$11,596,564$15,724,518

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD DEF 14A filed April 21, 2021, accession 0001193125-21-124697, and prior-year filings. Open the filing on EDGAR.

How this page was built: the TEVA PHARMACEUTICAL INDUSTRIES LTD filed document, accession 0001193125-21-124697. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2021.

$17.0M
$32.5M
$11.6M
$15.7M
FY17
FY18
FY19
FY20
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
PSU375,752$3,626,007—
RSU260,190$2,510,834—
RSU232,776$2,246,288—
RSU226,173$2,182,569—
PSU198,938$1,919,752—
RSU179,104$1,728,354—
PSU87,951$848,727—
PSU72,275$697,454—
RSU63,613$613,865—
RSU53,734$518,533—
Option136,988—$18.61
Option197,241—$11.40

Per the Outstanding Equity Awards at Fiscal Year-End table in TEVA PHARMACEUTICAL INDUSTRIES LTD's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

TEVA PHARMACEUTICAL INDUSTRIES’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Kåre Schultz · this pagePresident and Chief Executive Officer$15,724,518
Hafrun FridriksdottirExecutive Vice President, Global Research and Development$4,290,333
Brendan O'GradyExecutive Vice President, North America Commercial$4,126,283
Eric DrapéExecutive Vice President, Global Operations$3,848,601
Eli KalifExecutive Vice President, Chief Financial Officer$3,723,815

The full TEVA PHARMACEUTICAL INDUSTRIES compensation record

free company brief

This page is one person within TEVA PHARMACEUTICAL INDUSTRIES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the TEVA PHARMACEUTICAL INDUSTRIES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TEVA PHARMACEUTICAL INDUSTRIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kåre Schultz's compensation dossier · One-time report. No refunds.